Compare IPHA & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | AMWL |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 179.6M |
| IPO Year | 2014 | 2020 |
| Metric | IPHA | AMWL |
|---|---|---|
| Price | $1.44 | $12.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | $6.67 | ★ $12.80 |
| AVG Volume (30 Days) | 55.5K | ★ 85.1K |
| Earning Date | 09-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $390.56 | N/A |
| Revenue Next Year | $143.06 | $3.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $3.71 |
| 52 Week High | $2.71 | $14.19 |
| Indicator | IPHA | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 41.95 |
| Support Level | $1.34 | $11.99 |
| Resistance Level | $1.83 | $13.92 |
| Average True Range (ATR) | 0.10 | 0.68 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 6.76 | 5.93 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.